Menu

GLP-1 food industry impact: five questions for the board

GLP-1 food industry impact: five questions for the board

Home » Insights » GLP-1 food industry impact: five questions for the board
The GLP-1 impact on the food industry is a portfolio problem, not a labelling problem. A “GLP-1 friendly” sticker does not change why a household buys less of your brand.

GLP-1 food industry impact starts with the basket

GLP-1 drugs reduce appetite and cravings. Therefore, the first effect is on volume, and it falls hardest on the categories bought for craving or reward. AJ van Triest, a former senior marketer at Unilever and FrieslandCampina who now works on public health, makes a second point. Food is a social habit. If one person in a household uses these drugs, the whole family tends to eat differently. In his words, we are “less individualistic than we think”. So the unit of demand is the household repertoire, not the individual buyer. Most families cook five or six recipes and repeat them week after week. Your brand either sits in that rotation or it does not.

From ingredient accountability to impact accountability

For years, food companies have been judged on what is in the product. Sugar, fat and salt came first, then fibre and protein. Van Triest argues that the test is moving to what the product does in the body. Satiety, energy and metabolic impact are the new questions. He points to three forces that arrive together. Consumers want products with a visible health outcome. Nutrition science is shifting from safe food to outcome-driven food. In addition, governments face rising healthcare bills and look to producers. He puts chronic disease at roughly 70% of healthcare costs. He also notes that supermarkets matter more than most manufacturers assume. By his estimate, retailers produce about 60% of the calories eaten in Western Europe, mainly through private label and fresh food. A retailer that promotes a dish in week 48 shapes what a large share of a country eats that week.

What GLP-1 users actually do

Pippa Bailey, Head of Strategy and Innovation at CRG Global, tracks GLP-1 users in consumer research. She groups them into four types. They are clinical users, event-based on-off users, people managing cost or side effects, and people still considering the drugs. Her findings are worth testing against your own data. In her panel of 2,000 respondents, 36 to 37% said they had used or were using GLP-1. A published estimate she cited was 12%. Her panel is not a national sample, so treat the figure as a signal and not as prevalence. Her description of the reward effect is direct. Foods that users once craved become things they “can’t even look at”. She is cautious about claims on taste, however. She says that a shift in sweetness perception is unproven and that proper studies are needed. Her practical advice for research teams is simple. Do not screen users out of your studies. Instead, over-sample them, because historic norms and benchmarks may stop being valid once a third of consumers are affected.

Which GLP-1 food industry portfolios are most exposed

Van Triest expects the losers to be categories driven by craving. The likely winners are real food made convenient. His rule is to make the convenient option healthier, not to make the healthy option more convenient. He also separates daily products from occasional ones. A product eaten weekly by millions of families carries more health responsibility than a treat. For example, if a frozen pizza is pushed as a weekly occasion, it crowds out other meals in the repertoire. Many companies respond with a label or a small-pack launch. However, these moves treat the drug as a trend to tap rather than as a change in the demand base.

Five questions for the board

First, split the portfolio into daily and occasional products. Then check how much of your volume depends on craving. Second, map the household repertoire. Find where your brand sits in the week and what it replaces. Third, over-sample GLP-1 users in research. Rebuild the norms you use to approve and rank new products. Fourth, work with retailers on outcomes. They hold the basket data that shows what households really buy. Fifth, put one executive in charge of the health question. Van Triest suggests a board-level owner, because health sits across R&D, marketing and regulatory teams. His summary question is the one worth bringing to the next portfolio review. If your products are eaten often and in large amounts, what is the health outcome of that consumption? A portfolio that cannot answer it will be answering to a regulator or a retailer instead. To apply this to your own business, see the Growth OS programme or the FMCG Growth Sprint.

No Comments yet!

This site uses Akismet to reduce spam. Learn how your comment data is processed.